Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation-Reference-Cited by-同舟云学术

Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation

Published:2019-02-19 Issue:5 Volume:93 Page:934-948
ISSN:1747-0277
Container-title:Chemical Biology & Drug Design
language:en
Short-container-title:Chem Biol Drug Des

Author:

Wang Yu¹²,Peng Cheng²,Wang Guimin²,Xu Zhijian²,Luo Yongfeng¹,Wang Jinan²^ORCID,Zhu Weiliang²

Affiliation:

1. Hunan Province Key Laboratory of Materials Surface & Interface Science and TechnologyCollege of ScienceCentral South University of Forestry and Technology Changsha Hunan China

2. CAS Key Laboratory of Receptor ResearchDrug Discovery and Design CenterShanghai Institute of Materia MedicaChinese Academy of Sciences Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Molecular Medicine,Biochemistry,Drug Discovery,Pharmacology,Organic Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cbdd.13493

Reference60 articles.

1. Lenvatinib treatment of advanced RAI‐refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response;Ball D. W.;Journal of Clinical Oncology,2012

2. Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma

3. Molecular mechanisms and clinical applications of angiogenesis